What is the "Egrifta (visceral fat)" protocol for Tesamorelin?

2 mg · Daily s.c. · 26 weeks (standard)

Dosing

Tesamorelin (Egrifta) - dosing protocol

Tesamorelin (FDA-approved) is dosed at 2 mg under the skin (s.c. injection) daily. Selective visceral fat (around the organs) reduction — 15-18% over 26 weeks in HIV lipodystrophy (Falutz, NEJM 2007). Does not affect subcutaneous fat.

Route

Subcutaneous (s.c.) — abdomen

Dose

1-2 mg / daily

Half-life

~26 minutes

Storage

-20°C lyophilized; reconstituted — 7 days at 2-8°C

Dosing regimens

Standard regimens from the literature. The choice depends on what you're trying to achieve.

Protocol

Egrifta (visceral fat)

Dose: 2 mg
Frequency: Daily s.c.
Duration: 26 weeks (standard)

Side effects

The FDA-approved profile includes arthralgia (joint pain, 8%), peripheral edema (5%), paresthesia (numbness/tingling, 4%) — mostly from growth-hormone signaling. Glycemic monitoring, including HbA1c (long-term blood sugar), is recommended in clinical protocols.

See full side-effect list

Encyclopedia

Full scientific profile for Tesamorelin

Calculator

What does this protocol cost per day?

Last reviewed: 6 May 2026by PeptidLabs Editorial